Abstract:Background Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) is a standard for stratifying high-risk hepatocellular carcinoma (HCC) patients. In CEUS LI-RADS version 2017, the CEUS features are evaluated using pure-blood pool contrast agent, which might be inapplicable to perfluorobutane contrast agent in terms of Kupffer phase defect. Purpose This study aims to summarize and compare diagnostic performance of classical with modified CEUS LI-RADS using perfluorobutane by integrating published data and our original study data from three medical centers. Methods • PubMed, Embase, Cochrane library and Web of Science were searched up to 31 August, 2023, observational (retrospective or prospective) or clinical trials of perfluorobutane contrast agent in diagnosing HCC in high-risk patients were included. • Quality Assessment of Diagnostic Accuracy Studies-2 tool was used. • Comparison between classical and modified CEUS LI-RADS with perfluorobutane were performed by ranking of diagnostic odds ratio and superiority index using an ANOVA arm-based model. • PROSPERO registration number: CRD42023461549. Key Results Nine studies plus our original data were included in this meta-analysis, relating to 1662 patients with 1779 lesions. 1. The summarized sensitivity of modified CEUS LI-RADS was higher than classical CEUS LI-RADS (0.77[0.72-0.81] vs. 0.7[0.63-0.76]). 2. The general diagnostic performance of modified CEUS LI-RADS was superior than classical CEUS LI-RADS with a higher diagnostic odds ratio (16.98[11.65,23.43] vs. 12.51[8.11,18.44]) and higher superiority index (1.59[1.00,3.00] vs. 0.80[0.33,1.00]). Conclusions Modified CEUS LI-RADS using perfluorobutane contrast agent embraces better diagnostic performance with higher sensitivity without compromising specificity in high-risk HCC patients. Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) is a standard for stratifying high-risk hepatocellular carcinoma (HCC) patients. In CEUS LI-RADS version 2017, the CEUS features are evaluated using pure-blood pool contrast agent, which might be inapplicable to perfluorobutane contrast agent in terms of Kupffer phase defect. This study aims to summarize and compare diagnostic performance of classical with modified CEUS LI-RADS using perfluorobutane by integrating published data and our original study data from three medical centers. • PubMed, Embase, Cochrane library and Web of Science were searched up to 31 August, 2023, observational (retrospective or prospective) or clinical trials of perfluorobutane contrast agent in diagnosing HCC in high-risk patients were included. • Quality Assessment of Diagnostic Accuracy Studies-2 tool was used. • Comparison between classical and modified CEUS LI-RADS with perfluorobutane were performed by ranking of diagnostic odds ratio and superiority index using an ANOVA arm-based model. • PROSPERO registration number: CRD42023461549. Nine studies plus our original data were included in this meta-analysis, relating to 1662 patients with 1779 lesions. 1. The summarized sensitivity of modified CEUS LI-RADS was higher than classical CEUS LI-RADS (0.77[0.72-0.81] vs. 0.7[0.63-0.76]). 2. The general diagnostic performance of modified CEUS LI-RADS was superior than classical CEUS LI-RADS with a higher diagnostic odds ratio (16.98[11.65,23.43] vs. 12.51[8.11,18.44]) and higher superiority index (1.59[1.00,3.00] vs. 0.80[0.33,1.00]). Modified CEUS LI-RADS using perfluorobutane contrast agent embraces better diagnostic performance with higher sensitivity without compromising specificity in high-risk HCC patients.

Contrast‐enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta‐analysis

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Response to Letter to the Editor Regarding the Article "Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement" by Zhou and Collaborators

Comparison Between ACR CEUS LI-RADS and WFUMB-EFSUMB for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

DIAGNOSTIC PERFORMANCE OF CLASSICAL/MODIFIED CEUS LI-RADS WITH PERFLUOROBUTANE CONTRAST AGENT IN HIGH-RISK HEPATOCELLULAR CARCINOMA

Diagnostic Accuracy of Contrast-enhanced Ultrasonography Liver Imaging Reporting and Data System in Hepatocellular Carcinoma: A Systematic Review

Interobserver and inter-modalities agreement of contrast-enhanced ultrasound liver imaging reporting and data system(CEUS LI-RADS) and magnetic resonance imaging liver imaging reporting and data system(MRI LI-RADS) for hepatocellular carcinoma in high-risk patients

LI-RADS LR-5 on Contrast-Enhanced Ultrasonography Has Satisfactory Diagnostic Specificity for Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis

Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement

Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Diagnostic value of liver imaging reporting and data system for hepatocellular carcinoma by contrast-enhanced ultrasound

Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis

The Interreader Agreement and Validation of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System.

The efficacy of modified contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) using Sonazoid in diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

Inter‐Reader Agreement for Contrast‐Enhanced Ultrasound Liver Imaging Reporting and Data System Major Features and Final Categorization

Tumor Size-Based Validation of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) 2017 for Hepatocellular Carcinoma Characterizing.

Differences Between CEUS LI-RADS and CECT LI-RADS in the Diagnosis of Focal Liver Lesions in Patients at Risk for HCC

Contrast-enhanced Ultrasonography for the Diagnosis of Small Hepatocellular Carcinoma: a Meta-Analysis and Meta-Regression Analysis

Usefulness of the Contrast‐Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Focal Liver Lesions by Inexperienced Radiologists

Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 Mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.

LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison with Current LI-RADS Criteria